Drug-eluting stents (DES) are designed to reduce the extent of in-stent restenosis following percutaneous coronary intervention (PCI), via the controlled elution of an antimitotic drug such as ...

The trial evaluates R3 Vascular’s next generation drug eluting bioresorbable scaffold ... These are designed to deliver the ‘stent-like’ support of a scaffold along with the anti ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

The first drug-eluting stents (DESs) were approved by the FDA in 2003, after they were shown to significantly reduce rates of restenosis and repeat revascularization, when compared with bare-metal ...

LONDON, England—A recently approved drug-eluting bioresorbable scaffold for the treatment of below-the-knee (BTK) chronic limb-threatening ischemia (CLTI) is highly likely to be cost-effective for ...

CAD continues to be the most common cause of morbidity and mortality in the western world. A well known cause of CAD is atherosclerosis. [4] Although coronary artery bypass graft surgery has been ...

NICE has recommended that there is not enough evidence comparing drug-eluting stents to determine whether price variation between different stents is justified. NHS trusts should provide access to a ...

R3 Vascular is a privately-held medical device company that has developed a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds.

The trial evaluates R3 Vascular’s next generation drug eluting bioresorbable scaffold, MAGNITUDE®, for below-the-knee (BTK) PAD, which according to the American Heart Association affects more ...